Autologous and allogenic systems of HIV expansion:... - BV FAPESP
Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Autologous and allogenic systems of HIV expansion: what is the better choice for clinical application in therapeutic vaccine?

Full text
Author(s):
da Silva, Lais Teodoro [1] ; Pontillo, Alessandra [2, 1] ; da Silva, Wanessa Cardoso [1] ; de Almeida, Alexandre [1] ; da Silva Duarte, Alberto Jose [1] ; Oshiro, Telma Miyuki [1]
Total Authors: 6
Affiliation:
[1] Univ Sao Paulo, Fac Med, Dept Dermatol, Lab Med Invest Dermatol & Immunodeficiencies LIM, Sao Paulo - Brazil
[2] Univ Sao Paulo, Inst Biomed Sci, Dept Immunol, Immunogenet Lab, Sao Paulo - Brazil
Total Affiliations: 2
Document type: Journal article
Source: Immunotherapy; v. 5, n. 12, p. 1305-1311, DEC 2013.
Web of Science Citations: 0
Abstract

Aims: HIV-1 expanded in an allogenic system (Al-HIV) represents a cheaper and faster alternative to the autologous virus (Au-HIV) as an antigen in anti-HIV immunotherapy. In this study, chemically inactivated HIV-1 obtained through autologous or allogenic systems were compared. Patients \& methods: Au-HIV and Al-HIV obtained from cultures of peripheral blood mononuclear cells from 11 HIV+ individuals were tested for virus production, yield and time of culture, and their ability to elicit a specific immune response in vitro. Results: The allogenic system was more efficient than the autologous system. Dendritic cells pulsed with Au-HIV and Al-HIV presented a similar phenotypic profile, but only Al-HIV induced a significant increase in IFN-(+) lymphocytes. Conclusion: The use of an allogenic system displays several advantages in terms of cell manipulation, time and cost of culture, and immunogenicity. (AU)

FAPESP's process: 12/18879-6 - Characterization of dendritic cells used in an anti-HIV therapeutic vaccine clinical trial (Phase I/II)
Grantee:Telma Miyuki Oshiro Sumida
Support Opportunities: Regular Research Grants